These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32296913)

  • 21. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
    Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
    J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical analysis of the combination regimen with Bcl-2 inhibitor venetoclax in the treatment of 30 cases of acute myeloid leukemia with IDH1/2 mutation].
    Wang X; Bao XB; Zhang J; Song BQ; Li MY; Xie JD; Shen HJ; Wu DP; Qiu HY
    Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):691-694. PubMed ID: 36709157
    [No Abstract]   [Full Text] [Related]  

  • 23. In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site.
    Chaturvedi A; Goparaju R; Gupta C; Weder J; Klünemann T; Araujo Cruz MM; Kloos A; Goerlich K; Schottmann R; Othman B; Struys EA; Bähre H; Grote-Koska D; Brand K; Ganser A; Preller M; Heuser M
    Leukemia; 2020 Feb; 34(2):416-426. PubMed ID: 31586149
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enasidenib for patients with relapsed acute myeloid leukemia and the IDH2 mutation.
    DiNardo C
    Clin Adv Hematol Oncol; 2018 Apr; 16(4):247-249. PubMed ID: 29742078
    [No Abstract]   [Full Text] [Related]  

  • 25. Persistence of mutant isocitrate dehydrogenase in patients with acute myeloid leukemia in remission.
    Chou WC; Peng KY; Lei WC; Ko BS; Tsay W; Kuo CH; Tien HF
    Leukemia; 2012 Mar; 26(3):527-9. PubMed ID: 21844873
    [No Abstract]   [Full Text] [Related]  

  • 26. Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results.
    Heuser M; Palmisiano N; Mantzaris I; Mims A; DiNardo C; Silverman LR; Wang ES; Fiedler W; Baldus C; Schwind S; Pardee T; Perl AE; Cai C; Kaulfuss S; Lagkadinou E; Rentzsch C; Wagner M; Wilkinson G; Wu B; Jeffers M; Genvresse I; Krämer A
    Leukemia; 2020 Nov; 34(11):2903-2913. PubMed ID: 32733012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
    DiNardo CD; Stein EM; de Botton S; Roboz GJ; Altman JK; Mims AS; Swords R; Collins RH; Mannis GN; Pollyea DA; Donnellan W; Fathi AT; Pigneux A; Erba HP; Prince GT; Stein AS; Uy GL; Foran JM; Traer E; Stuart RK; Arellano ML; Slack JL; Sekeres MA; Willekens C; Choe S; Wang H; Zhang V; Yen KE; Kapsalis SM; Yang H; Dai D; Fan B; Goldwasser M; Liu H; Agresta S; Wu B; Attar EC; Tallman MS; Stone RM; Kantarjian HM
    N Engl J Med; 2018 Jun; 378(25):2386-2398. PubMed ID: 29860938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic targeting of isocitrate dehydrogenase mutant AML.
    Boddu P; Borthakur G
    Expert Opin Investig Drugs; 2017 May; 26(5):525-530. PubMed ID: 28388242
    [No Abstract]   [Full Text] [Related]  

  • 29. Ivosidenib to treat adult patients with relapsed or refractory acute myeloid leukemia.
    Pasquier F; Lecuit M; Broutin S; Saada S; Jeanson A; Penard-Lacronique V; de Botton S
    Drugs Today (Barc); 2020 Jan; 56(1):21-32. PubMed ID: 32055803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome of relapsed/refractory AML patients with IDH1
    Largeaud L; Bertoli S; Bérard E; Dufrechou S; Prade N; Gadaud N; Tavitian S; Bories P; Luquet I; Sarry A; Mas V; Huguet F; Delabesse E; Récher C
    Leuk Lymphoma; 2020 Feb; 61(2):473-476. PubMed ID: 31566052
    [No Abstract]   [Full Text] [Related]  

  • 31. Frequent reconstitution of IDH2(R140Q) mutant clonal multilineage hematopoiesis following chemotherapy for acute myeloid leukemia.
    Wiseman DH; Williams EL; Wilks DP; Sun Leong H; Somerville TD; Dennis MW; Struys EA; Bakkali A; Salomons GS; Somervaille TC
    Leukemia; 2016 Sep; 30(9):1946-50. PubMed ID: 27118404
    [No Abstract]   [Full Text] [Related]  

  • 32. IDH1 inhibitor-induced neutrophilic dermatosis in a patient with acute myeloid leukemia.
    Dunn-Valadez S; Bathini S; Elston C; Rangaraju S; Stasi AD; Worth S; Morlote D; Harada S; Vachhani P
    Cancer Treat Res Commun; 2022; 31():100560. PubMed ID: 35460975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of adult patients with acute myeloid leukemia (excluding acute promyelocytic leukemia)].
    Usui N
    Rinsho Ketsueki; 2014 Oct; 55(10):1808-16. PubMed ID: 25297744
    [No Abstract]   [Full Text] [Related]  

  • 34. 2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels.
    Pollyea DA; Kohrt HE; Zhang B; Zehnder J; Schenkein D; Fantin V; Straley K; Vasanthakumar A; Abdel-Wahab O; Levine R; Godley LA; Medeiros BC
    Leuk Lymphoma; 2013 Feb; 54(2):408-10. PubMed ID: 22680765
    [No Abstract]   [Full Text] [Related]  

  • 35. [Clinical characteristics of newly diagnosed acute myeloid leukemia patients with NPM1 mutation].
    Wei H; Zhang YQ; Lin D; Wang Y; Zhou CL; Liu BC; Li W; Rao Q; Wang M; Mi YC; Wang JX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):11-5. PubMed ID: 24598642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NPM1-mutant acute myeloid leukemia relapsing as acute lymphoblastic leukemia with clonal persistence of IDH1 mutation.
    Raman HS; Shanmugam V; Li J; Steensma DP; Kim AS; Luskin MR
    Leuk Lymphoma; 2021 Jul; 62(7):1790-1792. PubMed ID: 33586600
    [No Abstract]   [Full Text] [Related]  

  • 37. Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia.
    Gangat N; McCullough K; Abdelmagid M; Karrar O; Powell M; Al-Kali A; Alkhateeb H; Begna K; Mangaonkar A; Saliba A; Torghabeh MH; Litzow M; Hogan W; Shah M; Patnaik M; Pardanani A; Badar T; Foran J; Palmer J; Sproat L; Yi CA; Tefferi A
    Haematologica; 2024 Jan; 109(1):187-292. PubMed ID: 37534525
    [No Abstract]   [Full Text] [Related]  

  • 38. Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia.
    Chaturvedi A; Gupta C; Gabdoulline R; Borchert NM; Goparaju R; Kaulfuss S; Görlich K; Schottmann R; Othman B; Welzenbach J; Panknin O; Wagner M; Geffers R; Ganser A; Thol F; Jeffers M; Haegebarth A; Heuser M
    Haematologica; 2021 Feb; 106(2):565-573. PubMed ID: 32241846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of preleukemic mutations and their persistence on hematologic recovery after induction chemotherapy for AML.
    Murphy T; Zou J; Daher-Reyes GS; Arruda A; Gupta V; McNamara CJ; Minden MD; Schimmer AD; Sibai H; Yee KWL; Korulla M; Stockley T; Kamel-Reid S; Maze D; Tierens A; Bratman SV; Schuh AC; Chan SM
    Blood Adv; 2019 Aug; 3(15):2307-2311. PubMed ID: 31371380
    [No Abstract]   [Full Text] [Related]  

  • 40. Targeting isocitrate dehydrogenase (IDH) in cancer.
    Fujii T; Khawaja MR; DiNardo CD; Atkins JT; Janku F
    Discov Med; 2016 May; 21(117):373-80. PubMed ID: 27355333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.